Purpose

The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age > 18 years of age. - Is undergoing one or more procedures to address the included fractures listed below for one or more (at least one) HELEF at high-risk for SSI: - Open tibia fractures - Open femur fractures - Open or closed tibial plateau fractures - Open or closed tibial pilon fractures - Open or closed calcaneus fractures - Open or closed talus fractures - Open or closed foot fractures of any bone EXCEPT the toes - Open fibula fractures - Open rotational ankle fractures (malleoli) - Open or closed leg fractures associated with compartment syndrome - Examples of included procedures: - Excisional debridement of open fracture, femur and/or tibia - Intramedullary nail, tibia (open injury) - Intramedullary nail, femur (open injury) - Open reduction Pilon/Plafond fracture - Open reduction tibial plateau fracture - Open reduction calcaneal fracture - Open reduction Lisfranc/metatarsal associated with crush injury - Open reduction talus - External fixation, lower extremity tibia or femur associated with open fracture or compartment syndrome - Fasciotomy, lower extremity for compartment syndrome related to femur, tibia, or foot fracture - Lower extremity amputation related to HELEF

Exclusion Criteria

  • Documented or verbalized sensitivity or allergy to iodine or iodine-based contrast. - Known pregnancy in women. - Active bacterial infection at the HELEF site. - Incarcerated persons. - Persons who cannot follow up at the participating site (e.g., people who are homeless at the time of the injury or people with intellectual challenges who lack the social support for follow up visits). - Patients with facial fractures or other conditions that preclude nasal swabbing. - Patients who do not speak English or Spanish.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Nasal Povidone-Iodine Decolonization Intervention
Intranasal povidone-iodine (PDI Profend) will be applied to the patients' noses 60 minutes before surgery to repair HELEF and approximately 12 hours after the first application. If the patient will have additional HELEF repair in the 6 month followup period, intranasal PVI will be applied in a similar manner for each procedure.
  • Drug: povidone-iodine topical ointment
    Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
    Other names:
    • Profend
No Intervention
Concurrent Control
Standard of Care. This will be usual care at each participating site for subjects enrolled in the Baseline period.

Recruiting Locations

Washington University in St. Louis and nearby locations

Washington University
St Louis 4407066, Missouri 4398678 63110
Contact:
Anna Miller
milleran@wustl.edu

More Details

NCT ID
NCT05763602
Status
Recruiting
Sponsor
Loreen Herwaldt

Study Contact

Loreen Herwaldt, MD
+1 319 356 0474
loreen-herwaldt@uiowa.edu

Detailed Description

These patients are at high risk of SSI but given the rapidity with which they need their operations, interventions that take time are difficult or impossible to use in this patient population. This study will involve identifying patients with HELEF and applying PVI to their nares within 60 minutes before their surgical incisions are made and again approximately 12 hours after the first dose. The investigators will abstract information from the patients' medical records about their demographics, underlying illnesses, injury severity, the surgical procedures, and SSI for the 6 months following their operations and the investigators will see them during their routinely scheduled visit at about 6 months to ask them whether they were treated for SSI by providers outside of our system. For patients who do not return for follow up, the investigators will try to contact them to determine if they had signs or symptoms of SSI or were treated for SSI outside of our system.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.